Page last updated: 2024-11-05

ticlopidine and Graft Occlusion, Vascular

ticlopidine has been researched along with Graft Occlusion, Vascular in 168 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.

Research Excerpts

ExcerptRelevanceReference
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."9.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."9.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."9.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."7.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."7.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."7.70Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis."6.15Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."5.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding."5.22Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016)
"The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial."5.19The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014)
"The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)."5.17Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013)
"Clopidogrel reduces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proportion of fistulas that become suitable for dialysis."5.13Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. ( Allon, M; Beck, GJ; Braden, GL; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Gassman, JJ; Greenberg, A; Greene, T; Himmelfarb, J; Ikizler, TA; Kaufman, JS; Kusek, JW; Meyers, CM; Radeva, MK; Rocco, MV; Vazquez, MA, 2008)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."4.90Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel."4.90Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014)
"The optimal length of clopidogrel therapy in patients with acute coronary syndromes or in those who have undergone percutaneous coronary intervention (PCI) remains controversial."4.87Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. ( Gaglia, MA; Waksman, R, 2011)
" Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease."4.85Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009)
" The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding."3.83Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016)
" No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)."3.81Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015)
"The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated."3.78Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012)
"The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI."3.78Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012)
"AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)."3.77Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011)
"The case is reported of a patient presenting with recurrent acute myocardial infarction due to stent thrombosis resulting from possible clopidogrel resistance caused by interaction between clopidogrel and anti-tuberculosis drugs."3.74Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance. ( Smith, D; Srinivasan, M, 2008)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."3.70Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"The efficacy of a postoperative treatment with Low molecular weight heparin (LMWH) vs Ticlopidine in controlling early thrombosis, intimal hyperplasia and growth of true endothelial cells in small prosthetic expanded polytetrafluoroethylene (ePTFE) grafts (4 mm) interposed in the carotid artery of sheep has been evaluated."3.69Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study. ( Baccini, P; Bachi, V; Ceppa, P; Civalleri, D; Decian, F; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1996)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."2.79Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
"Reactive thrombocytosis has been reported in 20% of patients after coronary artery bypass grafting (CABG), a frequency that might be related to the high incidence of thrombotic complications."2.73The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. ( Alper, AT; Ates, M; Demirtas, MM; Gunay, R; Idiz, M; Kayacioglu, I; Saskin, H; Sensoz, Y; Tangurek, B; Yekeler, I, 2008)
"Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%."2.73Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. ( Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008)
"People with end-stage renal disease (ESRD) often require either the formation of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for haemodialysis."2.72Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Kamarizan, MFA; Mohamed, I, 2021)
"Probucol is a lipid-lowering drug that has an antioxidant effect."2.70Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002)
" No in-hospital adverse cardiac events occurred."2.69beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. ( Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999)
" Side-effects of ticlopidine were rare and patient management with the standard dosage of this drug was easier than oral anticoagulation."2.66Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. ( Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M, 1985)
"Ticlopidine is an effective inhibitor of platelet aggregation."2.66Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. ( Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R, 1985)
"Acute coronary syndrome was the indication for index-PCI in 74% of the patients."1.46High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. ( Godschalk, TC; Kelder, JC; Ten Berg, JM; Zwart, B, 2017)
"Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)."1.35Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009)
"Intimal hyperplasia is a major cause of restenosis after the interventional or surgical treatment of occlusive arterial disease."1.35Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass. ( Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S, 2009)
" We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk."1.31Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001)
"to investigate the effect of clopidogrel combined with aspirin or aspirin alone on fibromyointimal hyperplasia (FIMH) in a bypass model with native vein grafts (NVG) and biocompound grafts (BCG)."1.31Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. ( Gutersohn, A; Hetzer, R; Mülling, C; Musci, M; Sänger, S; Schaffner, T; Wellnhofer, E; Zurbrügg, HR, 2001)
"The composition of the thrombus is analyzed by double isotope labeling of platelets and fibrinogen."1.28[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats]. ( Cazenave, JP; Freund, M; Mantz, F, 1991)
"The dry weight of thrombus in the graft in group B and group D was 39 +/- 3 mg and 30 +/- 2 mg, respectively on day 28."1.28The pathogenesis of thrombosis in venous prostheses. ( Itoh, T; Kambayashi, J; Kawasaki, T; Mori, T; Sakon, M; Shiba, E; Watase, M, 1990)

Research

Studies (168)

TimeframeStudies, this research(%)All Research%
pre-199011 (6.55)18.7374
1990's22 (13.10)18.2507
2000's66 (39.29)29.6817
2010's68 (40.48)24.3611
2020's1 (0.60)2.80

Authors

AuthorsStudies
Mohamed, I1
Kamarizan, MFA1
Da Silva, A1
Sukul, D1
Seth, M1
Dixon, SR1
Khandelwal, A1
LaLonde, TA1
Gurm, HS1
Li, R1
Lan, B1
Zhu, T1
Yang, Y1
Cai, M1
Fang, Z1
Ma, C1
Chen, S1
Redfors, B1
Ben-Yehuda, O1
Lin, SH1
Furer, A1
Kirtane, AJ2
Witzenbichler, B1
Weisz, G1
Stuckey, TD1
Maehara, A1
Généreux, P3
Giustino, G1
Rinaldi, MJ1
Neumann, FJ5
Metzger, DC1
Henry, TD1
Cox, DA1
Duffy, PL1
Mazzaferri, EL1
Ayele, GM1
Mehran, R1
Mintz, GS1
Stone, GW4
Zwart, B2
Godschalk, TC1
Kelder, JC2
Ten Berg, JM4
Tong, MS1
Sung, PH1
Liu, CF1
Chen, KH1
Chung, SY1
Chua, S1
Chen, CJ1
Lee, WC1
Chai, HT1
Yip, HK1
Chang, HW1
Deo, SV1
Dunlay, SM1
Shah, IK1
Altarabsheh, SE1
Erwin, PJ1
Boilson, BA1
Park, SJ2
Joyce, LD1
Jerzewski, K1
Ruel, M2
Voisine, P2
Le May, MR1
Kulik, A2
Pennacchi, M1
Stio, RE1
Lucisano, L1
Calcagno, S1
Mancone, M1
Sardella, G1
Une, D1
Le May, M1
Ebrahimi, R1
Bakaeen, FG1
Uberoi, A1
Ardehali, A1
Baltz, JH1
Hattler, B1
Almassi, GH1
Wagner, TH1
Collins, JF1
Grover, FL1
Shroyer, AL1
Silber, S1
Belardi, JA1
Liu, M2
Brar, S1
Rothman, M1
Windecker, S2
Camenzind, E1
Boersma, E1
Wijns, W1
Mauri, L1
Rademaker-Havinga, T1
Ordoubadi, FF1
Suttorp, MJ1
Al Kurdi, M1
Steg, PG4
Husted, S2
James, SK2
Bach, RG1
Becker, RC2
Budaj, A1
Heras, M1
Himmelmann, A2
Horrow, J1
Katus, HA2
Lassila, R1
Morais, J1
Nicolau, JC1
Storey, RF2
Wojdyla, D1
Wallentin, L2
Loh, JP1
Torguson, R4
Pendyala, LK1
Omar, A1
Chen, F1
Satler, LF5
Pichard, AD5
Waksman, R6
Guo, B1
Tan, Q1
Guo, D1
Shi, Z1
Zhang, C1
Guo, W1
Kakisis, JD1
Vassilas, K1
Antonopoulos, C1
Sfyroeras, G1
Moulakakis, K1
Liapis, CD1
Parekh, P1
Agrawal, N1
Vasavada, A1
Vinchurkar, M1
Hajj-Chahine, J1
Fu, Z1
Dong, W1
Shen, M1
Xue, H1
Guo, J1
Jing, J1
Han, Y2
Yang, X1
Chen, Y1
Hess, CN1
Lopes, RD2
Gibson, CM2
Hager, R1
Wojdyla, DM1
Englum, BR1
Mack, MJ1
Califf, RM1
Kouchoukos, NT1
Peterson, ED1
Alexander, JH1
Tantry, US2
Gesheff, M1
Liu, F1
Bliden, KP1
Gurbel, PA2
Timmers, L1
Stella, PR1
Agostoni, P1
Christ, G1
Siller-Matula, JM2
Francesconi, M1
Dechant, C1
Grohs, K1
Podczeck-Schweighofer, A1
Ferraris, VA1
Bolanos, MD1
Schulz-Schüpke, S1
Byrne, RA3
Adriaenssens, T1
Tölg, R1
Seyfarth, M1
Maeng, M1
Zrenner, B1
Jacobshagen, C1
Mudra, H2
von Hodenberg, E1
Wöhrle, J1
Angiolillo, DJ4
von Merzljak, B1
Rifatov, N1
Kufner, S1
Morath, T2
Feuchtenberger, A1
Ibrahim, T1
Janssen, PW1
Valina, C1
Li, Y1
Desmet, W1
Abdel-Wahab, M1
Tiroch, K1
Hengstenberg, C1
Bernlochner, I2
Fischer, M1
Schunkert, H1
Laugwitz, KL1
Schömig, A5
Mehilli, J5
Kastrati, A6
Jim, MH1
Wong, KL1
Yiu, KH1
Sueta, D1
Hokimoto, S1
Enomoto, K1
Ono, T1
Tabata, T1
Kajiwara, I1
Kaikita, K1
Saruwatari, J1
Oniki, K1
Nakagawa, K1
Ogawa, H1
Aradi, D1
Kirtane, A1
Bonello, L4
Huber, K3
Freynhofer, MK1
ten Berg, J1
Janssen, P1
Marcucci, R4
Patti, G1
Mangiacapra, F1
Valgimigli, M4
Morel, O1
Palmerini, T3
Price, MJ3
Cuisset, T1
Sibbing, D3
Liu, C1
Chen, D1
Liu, H1
Jiang, Q1
Lu, J2
Zuo, L1
Valenti, R2
Cantini, G1
Marrani, M1
Migliorini, A2
Carrabba, N1
Comito, V1
Vergara, R2
Cerisano, G1
Parodi, G1
Abbate, R3
Gori, AM3
Gensini, GF3
Antoniucci, D3
Gutierrez, JA1
Harrington, RA2
Blankenship, JC1
Hamm, CW1
Prats, J1
Deliargyris, EN1
Mahaffey, KW1
White, HD1
Bhatt, DL2
Briasoulis, A1
Palla, M1
Kagawa, Y1
Shiode, N1
Kawase, T1
Tamekiyo, H1
Okimoto, T1
Hayashi, Y1
Gargiulo, G1
Costa, F1
Ariotti, S1
Biscaglia, S1
Campo, G1
Esposito, G1
Leonardi, S1
Vranckx, P2
Shimada, YJ1
Bansilal, S1
Wiviott, SD1
Neely, B1
Cannon, CP3
Díaz-Villamarín, X1
Dávila-Fajardo, CL1
Martínez-González, LJ1
Carmona-Sáez, P1
Sánchez-Ramos, J1
Álvarez Cubero, MJ1
Salmerón-Febres, LM1
Cabeza Barrera, J1
Fernández-Quesada, F1
Camaro, C1
Damen, SA1
Brouwer, MA1
Kedhi, E1
Lee, SW3
Verdoia, M1
Barbieri, L1
Rognoni, A1
van T Hof, AW1
Ligtenberg, E1
de Boer, MJ1
Suryapranata, H1
De Luca, G1
Zhang, JJ1
Gao, XF1
Ge, Z1
Tian, NL1
Liu, ZZ1
Lin, S1
Ye, F1
Chen, SL1
Kukula, K1
Klopotowski, M1
Kunicki, PK1
Jamiolkowski, J1
Debski, A1
Bekta, P1
Polanska-Skrzypczyk, M1
Chmielak, Z1
Witkowski, A1
Della Riva, D1
Benedetto, U1
Bacchi Reggiani, L1
Feres, F1
Abizaid, A1
Gilard, M1
Morice, MC1
Hong, MK2
Kim, BK1
Jang, Y2
Kim, HS3
Park, KW2
Colombo, A1
Chieffo, A1
Sangiorgi, D1
Biondi-Zoccai, G1
Angelini, GD1
Pufulete, M1
White, J1
Kayacioglu, I1
Gunay, R1
Saskin, H1
Idiz, M1
Sensoz, Y1
Ates, M1
Tangurek, B1
Alper, AT1
Demirtas, MM1
Yekeler, I1
Moschi, G1
Paniccia, R2
Buonamici, P2
Trenk, D1
Hentschel, DM1
Asif, A1
Wusirika, R1
Rao, P1
Fourtounas, C1
Vlachojannis, JG1
Camoin-Jau, L1
Armero, S1
Com, O1
Arques, S1
Burignat-Bonello, C1
Giacomoni, MP1
Bonello, R1
Collet, F1
Rossi, P1
Barragan, P2
Dignat-George, F1
Paganelli, F1
Stegherr, J1
Latz, W1
Koch, W2
Dörrler, K1
von Beckerath, N1
Milani, RV1
Roy, P1
Okabe, T1
Pinto Slottow, TL2
Steinberg, DH1
Kaneshige, K2
Xue, Z3
Kent, KM2
Suddath, WO3
Lindsay, J2
Giusti, B1
Saracini, C1
Sestini, I1
Dean, J1
Yujie, Z1
Yingxin, Z1
Yuyang, L1
Yonghe, G1
Wanjun, C1
Zheng, C1
Berger, PB2
Teirstein, PS1
Tanguay, JF1
Kandzari, DE1
Topol, EJ1
Butler, MJ1
Eccleston, D1
Clark, DJ1
Ajani, AE2
Andrianopoulos, N1
Brennan, A1
New, G1
Black, A1
Szto, G1
Reid, CM1
Yan, BP1
Shaw, JA1
Dart, AM1
Duffy, SJ1
Pecot, CV1
Fuller, M1
Muldowney, JA1
Misra, S1
Gao, C1
Ren, C1
Li, D1
Li, L1
Esposito, RA1
Wang, ZJ1
Zhou, YJ1
Liu, YY1
Yu, M1
Shi, DM1
Zhao, YX1
Guo, YH1
Cheng, WJ1
Nie, B1
Ge, HL1
Jia, DA1
Yang, SW1
Yan, ZX1
Schulz, S2
Schuster, T1
Ellert, J1
Massberg, S2
Goedel, J1
Bruskina, O1
Ulm, K1
Gavini, R1
Beauzile, P1
Sushinsky, SJ1
Scheinowitz, M1
Tantry, U1
Kent, K1
Gurbel, P1
Wilson, AM1
Brittenden, J1
Bachoo, P1
Ford, I1
Nixon, GF1
Geisler, T1
Zürn, C1
Simonenko, R1
Rapin, M1
Kraibooj, H1
Kilias, A1
Bigalke, B1
Stellos, K1
Schwab, M1
May, AE1
Herdeg, C1
Gawaz, M1
Mazighi, M1
Saint Maurice, JP1
Bresson, D1
Szatmary, Z1
Houdart, E1
Montalescot, G1
Hulot, JS1
Collet, JP1
Yucel, S1
Bahcivan, M1
Gol, MK1
Erenler, BH1
Kolbakir, F1
Keceligil, HT1
Popescu, WM1
Chun, KJ1
Park, SW1
Kim, YH1
Yun, SC1
Kim, WJ2
Lee, JY2
Park, DW1
Lee, CW1
Rhee, KS1
Chae, JK1
Ko, JK1
Park, JH1
Lee, JH1
Choi, SW1
Jeong, JO1
Seong, IW1
Jon, S1
Cho, YH1
Lee, NH1
Kim, JH1
Flores-Ríos, X1
Aldama-López, G1
Calviño-Santos, RA1
Vázquez-González, N1
Castro-Beiras, A1
Belch, JJ1
Dormandy, J1
Biasi, GM1
Biasi, BM1
Cairols, M1
Diehm, C1
Eikelboom, B1
Golledge, J1
Jawien, A1
Lepäntalo, M1
Norgren, L1
Hiatt, WR1
Becquemin, JP2
Bergqvist, D2
Clement, D1
Baumgartner, I1
Minar, E1
Stonebridge, P1
Vermassen, F1
Matyas, L1
Leizorovicz, A1
Harmsze, AM2
van Werkum, JW2
Bouman, HJ2
Breet, NJ2
van 't Hof, AW1
Ruven, HJ1
Hackeng, CM2
Klungel, OH1
de Boer, A1
Deneer, VH1
Gao, G1
Zheng, Z1
Pi, Y1
Lu, B1
Hu, S1
Sun, JC1
Teoh, KH1
Lamy, A1
Sheth, T1
Ellins, ML1
Jung, H1
Yusuf, S1
Anand, S1
Connolly, S1
Whitlock, RP1
Eikelboom, JW1
Kozuma, K1
Ota, Y1
Nagai, Y1
Katsuta, Y1
Nozaki, E1
Onodera, T1
Ikari, Y2
Kotani, J1
Kyo, E1
Yokoi, H1
Nakamura, M2
Mayer, K1
Refiker, M1
Conte, MS2
Koul, S1
Smith, JG1
Scherstén, F1
James, S1
Lagerqvist, B1
Erlinge, D1
Gaglia, MA1
Gasparovic, H1
Petricevic, M1
Biocina, B1
Bisdas, T1
Haverich, A1
Teebken, OE1
Avlonitis, VS1
Planas, S1
Hayes, AM1
Parry, A1
Warner, TD1
Mitchell, JA1
Kirkby, NS1
Sambu, N1
Radhakrishnan, A1
Dent, H1
Calver, AL1
Corbett, S1
Gray, H1
Simpson, IA1
Curzen, N1
Monaco, M1
Di Tommaso, L1
Pinna, GB1
Lillo, S1
Schiavone, V1
Stassano, P1
Kizilkilic, O1
Kocer, N1
Metaxas, GE1
Babic, D1
Homan, R1
Islak, C1
Kang, J1
Park, JJ1
Yang, HM1
Lee, HY1
Kang, HJ1
Koo, BK1
Oh, BH1
Park, YB1
Charlot, M1
Nielsen, LH1
Lindhardsen, J1
Ahlehoff, O1
Olsen, AM1
Hansen, ML1
Hansen, PR1
Madsen, JK1
Køber, L1
Gislason, GH1
Torp-Pedersen, C1
Jang, JS1
Jin, HY1
Seo, JS1
Yang, TH1
Kim, DK2
Kim, DS1
Seol, SH1
Kim, DI1
Cho, KI1
Kim, BH1
Park, YH1
Je, HG1
Jeong, YH1
Borghesi, M1
Tebaldi, M1
Parrinello, G1
Ferrari, R1
Pinnow, E1
Cheneau, E1
Leborgne, L1
Dieble, R1
Bui, AB1
Kent, KK1
Kim, MH1
Cha, KS1
Han, JY1
Kim, HJ1
Kim, JS1
Krötz, F1
Schiele, TM1
Zahler, S1
König, A1
Rieber, J1
Kantlehner, R1
Pöllinger, B1
Dühmke, E1
Theisen, K1
Sohn, HY1
Klauss, V1
Mueller, C1
Roskamm, H1
Hunziker, P1
Marsch, S1
Perruchoud, A1
Buettner, HJ1
Strike, PC1
Robinson, NM1
Dymond, DS1
Shechter, M1
Ortolani, P1
Marzocchi, A1
Gaiba, W1
Neri, S1
Marrozzini, C1
Aquilina, M1
Branzi, A1
Smout, JD1
Mikhailidis, DP1
Shenton, BK1
Stansby, G1
Jiménez-Quevedo, P1
Bernardo, E1
Sabaté, M2
Stiefelhagen, P1
Stein, PD2
Schünemann, HJ1
Dalen, JE2
Gutterman, D1
Tielliu, IF1
Verhoeven, EL1
Zeebregts, CJ1
Prins, TR1
Span, MM1
van den Dungen, JJ1
Takeyasu, N1
Watanabe, S1
Noguchi, Y1
Ishikawa, K1
Fumikura, Y1
Yamaguchi, I1
Mehta, SR1
Aranki, SF1
Michowitz, Y1
Blatt, A1
Frimmerman, A1
Finkelstein, A1
Massachi, R1
Herz, I1
Krakover, R1
Miller, H1
Keren, G1
George, J1
Wolak, A1
Zahger, D1
Ouriel, K1
Wholey, MH1
Fayad, P1
Katzen, BT1
Whitlow, P1
Frentzko, M1
Kuntz, RE2
Wechsler, L1
Hopkins, N1
Satler, L1
Mishkel, G1
Yadav, JS2
Bocek, P1
Dember, LM2
Kaufman, JS2
Beck, GJ2
Dixon, BS2
Gassman, JJ2
Greene, T2
Himmelfarb, J2
Hunsicker, LG1
Kusek, JW2
Lawson, JH1
Middleton, JP1
Radeva, M1
Schwab, SJ1
Whiting, JF1
Feldman, HI2
Kuchulakanti, PK1
Chu, WW1
Ohlmann, P1
Rha, SW1
Clavijo, LC1
Kim, SW1
Bui, A1
Gevorkian, N1
Smith, K1
Fournadjieva, J1
Jai Shankar, K1
Jaiswal, P1
Cherian, KM1
Ibrahim, K1
Tjomsland, O1
Halvorsen, D1
Wiseth, R1
Wahba, A1
Karevold, A1
Haaverstad, R1
Hata, M1
Sezai, A1
Niino, T1
Yoda, M1
Wakui, S1
Chiku, M1
Takayama, T1
Honye, J1
Saitoh, S1
Minami, K1
Luxembourg, B1
Mani, H1
Toennes, SW1
Strubel, G1
Klaeffling, C1
Daemgen-von Brevern, G1
Geisen, C1
Lindhoff-Last, E1
Prabhakaran, S1
Wells, KR1
Lee, VH1
Flaherty, CA1
Lopes, DK1
Srinivasan, M1
Smith, D1
Allon, M1
Delmez, JA1
Greenberg, A1
Vazquez, MA1
Radeva, MK1
Braden, GL1
Ikizler, TA1
Rocco, MV1
Davidson, IJ1
Meyers, CM1
Tonelli, M1
Garrido García, H1
Rivas Marín, J1
Vilaplana Serrano, F1
Martín Infante, A1
Lindblad, B1
Wakefield, TW1
Stanley, TJ1
Nichol, BJ1
Greenfield, LJ1
Stanley, JC1
Bergentz, SE1
Basile, AP1
Fiala, TG1
Yaremchuk, MJ1
May, JW1
Sainsous, J1
Silvestri, M1
Bouvier, JL1
Comet, B1
Siméoni, JB1
Villain, P1
Pietri, P1
Quatre, JM1
Bayet, G1
Hanaoka, T1
Eeckhout, E1
Kappenberger, L1
Goy, JL1
Simoni, G1
Galleano, R1
Civalleri, D1
Decian, F1
Desalvo, P1
Ceppa, P1
Baccini, P1
Lenti, E1
Bachi, V1
Belkin, M1
Donaldson, MC1
Whittemore, AD1
Gröntoft, KC2
Larsson, R1
Mulec, H2
Weiss, LG1
Dickinson, JP1
Makkar, RR1
Eigler, NL1
Kaul, S1
Frimerman, A1
Shah, PK1
Forrester, JS1
Herbert, JM1
Litvack, F1
Goldman, S1
Théroux, P1
Jackson, MR1
Clagett, GP1
Reifart, N1
Störger, H1
Schwarz, F1
Rabe, A1
Siegerstetter, V1
Huber, M1
Ochs, A1
Blum, HE1
Rössle, M1
Wardeh, AJ1
Kay, IP2
Coen, VL1
Gijzel, AL1
Ligthart, JM1
den Boer, A1
Levendag, PC1
van Der Giessen, WJ1
Serruys, PW1
Yoon, Y1
Shim, WH1
Lee, DH1
Pyun, WB1
Kim, IJ1
Cho, SY1
Van Langenhove, G2
Vermeersch, P2
Vaerenberg, M1
Heuten, H1
Stockman, D2
Convens, C2
Albertal, M2
Vrints, C1
Van den Branden, F2
Van den Heuvel, P2
Serrano, P1
Kutryk, MJ1
Vanagt, E1
Gottsauner-Wolf, M1
Zasmeta, G1
Hornykewycz, S1
Nikfardjam, M1
Stepan, E1
Wexberg, P1
Zorn, G1
Glogar, D1
Probst, P1
Maurer, G1
Dillon, WC1
Eckert, GJ1
Dillon, JC1
Ritchie, ME1
Dieter, RS1
Dirschinger, J1
Dotzer, F1
von Welser, N1
Kiesz, RS1
Buszman, P1
Martin, JL1
Deutsch, E1
Rozek, MM1
Gaszewska, E1
Rewicki, M1
Seweryniak, P1
Kosmider, M1
Tendera, M1
Shin, EK1
Son, JW1
Sohn, MS1
Jin, DK1
Park, GS1
Koh, KK1
Ahn, TH1
Choi, IS1
Cutlip, DE1
Baim, DS1
Ho, KK1
Popma, JJ1
Lansky, AJ1
Cohen, DJ1
Carrozza, JP1
Chauhan, MS1
Rodriguez, O1
Kuroda, Y1
Hara, K1
Nakajima, H1
Mukherjee, D1
Chew, DP1
Robbins, M1
Raymond, RE1
Moliterno, DJ1
Marx, SO1
Marks, AR1
Zurbrügg, HR1
Musci, M1
Sänger, S1
Gutersohn, A1
Mülling, C1
Wellnhofer, E1
Schaffner, T1
Hetzer, R1
Duran, E1
Canbaz, S1
Ege, T1
Acipayam, M1
Piamsomboon, C1
Laothavorn, P1
Chatlaong, B1
Saguanwong, S1
Nasawadi, C1
Tanprasert, P1
Leelaprute, M1
Intayakorn, U1
Amornsak, N1
Kambayashi, J2
Watase, M2
Itoh, T2
Kawasaki, T2
Shiba, E2
Sakon, M2
Mori, T2
Sagnol, P1
Delahaye, JP1
Mantz, F1
Freund, M1
Cazenave, JP1
Limet, R2
David, JL2
Magotteaux, P1
Larock, MP1
Rigo, P1
Harker, LA2
Verstraete, M1
Brown, BG1
Chesebro, JH1
Ekeström, S1
Henderson, AH1
Jewitt, DE1
Oliver, MF1
Sleight, P1
Kawana, S1
Katori, M1
Ohta, M1
Nishiyama, S1
Hansen, KJ1
Howe, HR1
Edgerton, TA1
Faust, KB1
Kon, ND1
Geisinger, KR1
Meredith, JH1
Fiskerstrand, CE1
Thompson, IW1
Burnet, ME1
Williams, P1
Anderton, JL1
Rothlin, ME1
Pfluger, N1
Speiser, K1
Goebel, N1
Krayenbühl, HP1
Steinbrunn, W1
Turina, M1
Senning, A1
Gutierrez, A1
Olander, R1

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119]Phase 3649 participants (Actual)Interventional2003-01-01Completed
Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients[NCT00912782]52 participants (Actual)Interventional2009-01-31Completed
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease[NCT01001351]Phase 1/Phase 289 participants (Actual)Interventional2009-09-30Completed
Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044]120 participants (Anticipated)Interventional2015-11-30Active, not recruiting
Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423]Phase 2113 participants (Actual)Interventional2006-05-31Completed
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]2,349 participants (Actual)Observational2008-08-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]1,516 participants (Actual)Interventional2008-07-31Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]100 participants (Actual)Interventional2009-03-31Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]Phase 42,292 participants (Actual)Interventional2008-04-30Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]Phase 48,709 participants (Actual)Interventional2007-06-30Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]Phase 318,624 participants (Actual)Interventional2006-10-31Completed
A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures[NCT00042081]Phase 33,000 participants Interventional2002-07-31Completed
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345]Phase 31,008 participants (Actual)Interventional2011-07-31Completed
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206]Phase 44,005 participants (Actual)Interventional2008-09-30Active, not recruiting
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial[NCT03078465]Phase 30 participants (Actual)Interventional2017-06-20Withdrawn (stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.)
Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475]Phase 3442 participants (Anticipated)Interventional2008-11-30Not yet recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300]Phase 2/Phase 3200 participants (Actual)Interventional2010-08-31Completed
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918]2,800 participants (Actual)Interventional2008-06-30Completed
Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237]70 participants (Actual)Interventional2016-06-30Completed
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]88 participants (Actual)Observational2018-01-01Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759]Phase 31,460 participants (Anticipated)Interventional2004-09-30Completed
Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786]Phase 42,700 participants (Actual)Interventional2011-06-30Completed
[NCT00776477]Phase 3300 participants (Anticipated)Interventional2007-12-31Recruiting
Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery[NCT00330772]Phase 3150 participants (Anticipated)Interventional2006-07-31Completed
Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014]1,000 participants (Anticipated)Observational2006-01-31Completed
Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703]Phase 349 participants (Actual)Interventional2009-01-31Completed
A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access[NCT02475837]Phase 217 participants (Actual)Interventional2015-08-26Completed
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis[NCT03289520]Phase 3877 participants (Actual)Interventional2003-01-07Completed
Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft VIG-only Study][NCT02532621]158 participants (Actual)Interventional2018-02-21Completed
Randomized Controlled Trial Comparing endoAVF Versus surgAVF[NCT05654103]90 participants (Anticipated)Interventional2024-02-01Not yet recruiting
Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease[NCT05457881]226 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Effects of Heparin on Early Patency of Arteriovenous Fistula in Angioaccess Surgery of Patients With End-Stage Renal Disease[NCT02493504]Phase 4150 participants (Actual)Interventional2011-01-31Completed
A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome[NCT03007524]Phase 480 participants (Anticipated)Interventional2016-07-31Recruiting
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]1,800 participants (Anticipated)Observational [Patient Registry]2018-11-21Not yet recruiting
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175]1,960 participants (Actual)Interventional2013-01-16Terminated (stopped due to Slow enrollment)
Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression[NCT01889992]Phase 142 participants (Actual)Interventional2013-04-24Terminated (stopped due to PI left University and project not continued)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Arteriovenous Fistulae Maturation

Maturation of an AVF is the ability to stick the AVF with two large bore needles at ≥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow >300 ml/min, assessed at six months following AVF creation. (NCT00912782)
Timeframe: 6 months

Interventionpercentage of group (Number)
Placebo50
Cholecalciferol40

25-hydroxyvitamin D and Serum Calcium

(NCT00912782)
Timeframe: 10 weeks

,
Interventionng/mL (Mean)
Serum 25 (OH) DSerum Calcium
Cholecalciferol53.48.8
Placebo18.49.1

Incidence of Major Adverse Coronary Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel4
Placebo5

Incidence of Major Bleeding Events Within One Year Following Surgery

(NCT00228423)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
75mg Clopidogrel1
Placebo0

Vein Graft Angiographic Patency

Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery

Interventionpercentage (Number)
75mg Clopidogrel94.3
Placebo93.2

Vein Graft Intimal Area

IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery

Interventionmm (Mean)
75mg Clopidogrel4.1
Placebo4.5

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Cardiac Death or Target Vessel MI4.2

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)0.9

Death

(NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group1.3

Major Adverse Cardiac Event (MACE)

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group5.5

Stent Thrombosis (ST)

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group0.1

Target Lesion Failure (TLF)

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Primary Enrollment Group4.7

Target Vessel Failure (TVF)

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group6.3

Target Vessel MI

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of eligible participants (Number)
Primary Enrollment Group1.4

In-stent Late Lumen Loss (LLL)

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Interventionmm (Mean)
Zotarolimus Eluting Stent0.13

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

Interventionpercentage of participants with TLF (Number)
Zotarolims Eluting Stent4.0

In-Stent Percent Diameter Stenosis

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

InterventionPercentage diameter stenosis (Mean)
1. Resolute - 12-13 Months21.65
2. XIENCE V - 12-13 Months19.76

Target Lesion Failure

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
1. Resolute - 12-13 Months8.2
2. XIENCE V - 12-13 Months8.3

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years

Interventionparticipants (Number)
E-ZES61
C-SES75

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

,
Interventionparticipants (Number)
Total death and large non-fatal myocardial infarctTotal death and non-fatal myocardial infarctionsCardiac death and large non-fatal MICardiac death and non-fatal MITarget lesion revascularizationStrokeBleeding events
C-SES25536017428215672184
E-ZES22533115726524977201

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR901
CLOPIDOGREL1065

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR1290
CLOPIDOGREL1456

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR569
CLOPIDOGREL668

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR864
CLOPIDOGREL1014

Participants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR961
CLOPIDOGREL929

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR619
CLOPIDOGREL654

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR329
CLOPIDOGREL341

Participants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR399
CLOPIDOGREL506

Participants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR353
CLOPIDOGREL442

Participants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR1339
CLOPIDOGREL1215

Participants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR504
CLOPIDOGREL593

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR362
CLOPIDOGREL306

Participants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR235
CLOPIDOGREL180

Participants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR125
CLOPIDOGREL106

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR21
CLOPIDOGREL16

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR84
CLOPIDOGREL51

Any Bleeding Event

"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy17
Individualized Therapy9

Definite Stent Thrombosis

"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days

Interventionparticipants (Number)
Standard Therapy1
Individualized Therapy0

Probable Stent Thrombosis

"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days

Interventionparticipants (Number)
Standard Therapy2
Individualized Therapy0

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

Number of Participants According to Bleeding Type/Etiology

For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
SpontaneousPuncture (vascular access site)
Clopidogrel 0.2 mg/kg/Day11
Placebo00

Number of Participants With Bleeding Events

"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
Any bleeding event- Serious- Serious with an outcome of death- Leading to permanent treatment discontinuation
Clopidogrel 0.2 mg/kg/Day2000
Placebo0000

Number of Participants With Shunt Thrombosis Requiring Intervention or Deaths

"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months

,
Interventionparticipants (Number)
shunt thrombosis requiring interventiondeath
Clopidogrel 0.2 mg/kg/Day00
Placebo01

Count of All Participants With Bleeding Events

Bleeding events according to GUSTO (criteria for bleeding: Severe, Moderate or Mild) and BARC (bleeding criteria Type 0-5, with 0 being no bleeding and 5 referring to probable or definite fatal bleeding) Criteria (NCT02475837)
Timeframe: up to 238 days

InterventionParticipants (Count of Participants)
Vorapaxar Intervention0
Placebo Intervention1

Count of Participants With AV Fistula Use

Participants able to use their AV fistula for dialysis within 180 days of surgery were considered to have met the outcome. (NCT02475837)
Timeframe: up to 238 days

InterventionParticipants (Count of Participants)
Vorapaxar Intervention2
Placebo Intervention4

Count Participants With AV Fistula Patency

Criteria for outcome: AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement. (NCT02475837)
Timeframe: 150-238 days

InterventionParticipants (Count of Participants)
Vorapaxar Intervention1
Placebo Intervention5

Time to AV Fistula Functional Maturation

Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks). (NCT02475837)
Timeframe: up to 238 days

InterventionDays to functional maturation (Median)
Vorapaxar Intervention169
Placebo Intervention145

Reviews

19 reviews available for ticlopidine and Graft Occlusion, Vascular

ArticleYear
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
    The Cochrane database of systematic reviews, 2021, 07-23, Volume: 7

    Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans;

2021
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
    Journal of cardiac surgery, 2013, Volume: 28, Issue:2

    Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl

2013
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Wandering stent within the pulmonary circulation.
    Annals of vascular surgery, 2014, Volume: 28, Issue:8

    Topics: Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Arteriovenous Shunt, Surgical;

2014
Resistance to antiplatelet drugs: what progress has been made?
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:17

    Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent

2014
Use of antiplatelet drugs after cardiac operations.
    Seminars in thoracic and cardiovascular surgery, 2014,Autumn, Volume: 26, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio

2014
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
    European heart journal, 2015, Jul-14, Volume: 36, Issue:27

    Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronar

2015
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
    Pharmacogenomics, 2016, Volume: 17, Issue:12

    Topics: Aged; Angioplasty; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cyto

2016
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
    European heart journal, 2017, 04-07, Volume: 38, Issue:14

    Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid

2017
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2009, Jul-01, Volume: 74 Suppl 1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas

2009
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes.
    European heart journal, 2011, Volume: 32, Issue:19

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule;

2011
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com

2012
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel

2004
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
    The Annals of thoracic surgery, 2005, Volume: 80, Issue:2

    Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coron

2005
Stents for intracoronary placement: current status and future directions.
    Journal of the American College of Cardiology, 1996, Mar-15, Volume: 27, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coro

1996
Antithrombotic therapy in peripheral arterial occlusive disease.
    Chest, 1998, Volume: 114, Issue:5 Suppl

    Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C

1998
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
    Presse medicale (Paris, France : 1983), 1991, Feb-23, Volume: 20, Issue:7

    Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me

1991
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical

1986

Trials

50 trials available for ticlopidine and Graft Occlusion, Vascular

ArticleYear
Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial.
    Journal of cardiothoracic surgery, 2013, Jul-10, Volume: 8

    Topics: Aged; Angiography; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Graft Occlusion,

2013
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
    Circulation, 2013, Sep-10, Volume: 128, Issue:11 Suppl 1

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ

2013
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
    Circulation, 2013, Sep-10, Volume: 128, Issue:11 Suppl 1

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ

2013
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
    Circulation, 2013, Sep-10, Volume: 128, Issue:11 Suppl 1

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ

2013
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
    Circulation, 2013, Sep-10, Volume: 128, Issue:11 Suppl 1

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ

2013
Effect of clopidogrel use post coronary artery bypass surgery on graft patency.
    The Annals of thoracic surgery, 2014, Volume: 97, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary

2014
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2014
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
    European heart journal, 2014, Jun-14, Volume: 35, Issue:23

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin

2014
Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.
    Circulation, 2014, Oct-21, Volume: 130, Issue:17

    Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Gra

2014
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
    European heart journal, 2015, May-21, Volume: 36, Issue:20

    Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug-

2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    European heart journal, 2016, Apr-07, Volume: 37, Issue:14

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora

2016
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    American heart journal, 2016, Volume: 174

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect

2016
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    American heart journal, 2016, Volume: 177

    Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular

2016
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    American heart journal, 2016, Volume: 178

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D

2016
The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.
    The heart surgery forum, 2008, Volume: 11, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Humans; Male; Middl

2008
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
    Journal of the American College of Cardiology, 2008, Aug-26, Volume: 52, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resista

2008
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
    The American journal of cardiology, 2009, Jan-01, Volume: 103, Issue:1

    Topics: Acute Disease; Aged; Angina Pectoris; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary T

2009
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female;

2009
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
    American heart journal, 2009, Volume: 157, Issue:5

    Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluti

2009
Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
    The Annals of thoracic surgery, 2009, Volume: 88, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Dose-Re

2009
Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
    Journal of vascular surgery, 2009, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Biomarkers; Blotting, Western; Cell P

2009
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
    The American journal of cardiology, 2010, Jan-15, Volume: 105, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
    Journal of vascular surgery, 2010, Volume: 52, Issue:4

    Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis

2010
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
    Journal of the American College of Cardiology, 2010, Nov-09, Volume: 56, Issue:20

    Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary A

2010
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
    American heart journal, 2010, Volume: 160, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Femal

2010
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati

2011
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
    Journal of vascular surgery, 2012, Volume: 56, Issue:1

    Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel;

2012
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
    European heart journal, 2013, Volume: 34, Issue:12

    Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy

2013
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
    Circulation, 2002, Aug-13, Volume: 106, Issue:7

    Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm

2002
Effect of antioxidant probucol for preventing stent restenosis.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2002, Volume: 57, Issue:4

    Topics: Aged; Antioxidants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Ar

2002
Sustained platelet activation following intracoronary beta irradiation.
    The American journal of cardiology, 2002, Dec-15, Volume: 90, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido

2002
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
    Journal of the American College of Cardiology, 2003, Mar-19, Volume: 41, Issue:6

    Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Ther

2003
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2004, Volume: 10, Issue:1

    Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug T

2004
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.
    Circulation journal : official journal of the Japanese Circulation Society, 2005, Volume: 69, Issue:7

    Topics: Aged; Cilostazol; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans;

2005
Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.
    AJNR. American journal of neuroradiology, 2008, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Cerebrovascular Disorders; Clopidogrel; C

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio

2008
Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie.
    The New England journal of medicine, 1997, Dec-11, Volume: 337, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Double-Blind Method; Female; Graft Occlusion, Vasc

1997
Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group.
    Scandinavian journal of urology and nephrology, 1998, Volume: 32, Issue:4

    Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Blood Vessel Prosthesis Implantation; Double-Blind Metho

1998
PTCA of degenerated vein grafts: experience of two periods (1992-93 and 1996-97) in 780 patients.
    Indian heart journal, 1998, Volume: 50 Suppl 1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Coronary Artery Bypass; Coro

1998
Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment.
    Hepatology (Baltimore, Md.), 1999, Volume: 29, Issue:1

    Topics: Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Graft Occlusion, Vascular

1999
beta-Particle-emitting radioactive stent implantation. A safety and feasibility study.
    Circulation, 1999, Oct-19, Volume: 100, Issue:16

    Topics: Adult; Aged; Aspirin; Beta Particles; Brachytherapy; Coronary Angiography; Coronary Disease; Feasibi

1999
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
    The American journal of cardiology, 1999, Dec-15, Volume: 84, Issue:12

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp

1999
Plasma levels of C-reactive protein after coronary stent implantation.
    European heart journal, 2000, Volume: 21, Issue:14

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Coronary An

2000
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.
    Circulation, 2000, Nov-21, Volume: 102, Issue:21

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adju

2000
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
    Circulation, 2001, Jan-02, Volume: 103, Issue:1

    Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll

2001
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2001, Volume: 84, Issue:12

    Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Drug Therapy, C

2001
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
    Presse medicale (Paris, France : 1983), 1991, Feb-23, Volume: 20, Issue:7

    Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me

1991
Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study.
    The Journal of thoracic and cardiovascular surgery, 1987, Volume: 94, Issue:5

    Topics: Angiography; Clinical Trials as Topic; Coronary Artery Bypass; Double-Blind Method; Electrocardiogra

1987
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
    Circulation, 1986, Volume: 73, Issue:2

    Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical

1986
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
    European heart journal, 1986, Volume: 7, Issue:1

    Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A

1986
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
    Artificial organs, 1985, Volume: 9, Issue:1

    Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft

1985
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
    European heart journal, 1985, Volume: 6, Issue:2

    Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypas

1985
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
    Scandinavian journal of urology and nephrology, 1985, Volume: 19, Issue:1

    Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind M

1985

Other Studies

101 other studies available for ticlopidine and Graft Occlusion, Vascular

ArticleYear
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:10

    Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethni

2017
Preventing graft restenosis after coronary artery bypass grafting with tissue-type plasminogen activator.
    European journal of medical research, 2017, Jun-12, Volume: 22, Issue:1

    Topics: Aged; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female;

2017
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
    The American journal of cardiology, 2017, Sep-15, Volume: 120, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combi

2017
High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS.
    Journal of interventional cardiology, 2017, Volume: 30, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Female; Graft Occlusion, V

2017
Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention.
    International heart journal, 2017, Oct-21, Volume: 58, Issue:5

    Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gast

2017
Five years on dual-antiplatelet therapy. DES thrombosis after clopidogrel withdrawal.
    International heart journal, 2013, Volume: 54, Issue:4

    Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Graft

2013
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
    The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal

2014
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
    Journal of vascular surgery, 2014, Volume: 60, Issue:4

    Topics: Aged; Alleles; Angiography, Digital Subtraction; Ankle Brachial Index; Arteriosclerosis Obliterans;

2014
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
    BMJ case reports, 2014, Jul-15, Volume: 2014

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu

2014
Clopidogrel after surgical coronary revascularization increases venous graft patency.
    The Annals of thoracic surgery, 2014, Volume: 98, Issue:2

    Topics: Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; Platelet

2014
Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention.
    Clinical biochemistry, 2014, Volume: 47, Issue:16-17

    Topics: Clopidogrel; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Percutaneous Coronary Int

2014
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
    European heart journal, 2015, Feb-07, Volume: 36, Issue:6

    Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio

2015
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    BMJ open, 2014, Oct-31, Volume: 4, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets;

2014
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
    International journal of cardiology, 2015, Apr-01, Volume: 184

    Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery By

2015
A case of repetitive and simultaneous stent thromboses.
    International journal of cardiology, 2015, Volume: 186

    Topics: Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Graft Occlu

2015
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
    Herz, 2015, Volume: 40, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr

2015
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
    International journal of cardiology, 2015, Dec-15, Volume: 201

    Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res

2015
Duration of dual antiplatelet therapy after coronary stenting.
    International journal of cardiology, 2016, Nov-01, Volume: 222

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Plat

2016
A case of subacute stent thrombosis after drug-coated balloon coronary angioplasty for in-stent restenosis under single anti-platelet therapy.
    Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Vessels; D

2017
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
    BMC cardiovascular disorders, 2016, 11-29, Volume: 16, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F

2016
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
    BMC cardiovascular disorders, 2016, 12-08, Volume: 16, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl

2016
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
    Journal of the American College of Cardiology, 2008, Aug-26, Volume: 52, Issue:9

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion

2008
Effect of clopidogrel on arteriovenous fistulas for dialysis.
    JAMA, 2008, Oct-08, Volume: 300, Issue:14

    Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation

2008
Effect of clopidogrel on arteriovenous fistulas for dialysis.
    JAMA, 2008, Oct-08, Volume: 300, Issue:14

    Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation

2008
Effect of clopidogrel on arteriovenous fistulas for dialysis.
    JAMA, 2008, Oct-08, Volume: 300, Issue:14

    Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation

2008
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
    European heart journal, 2009, Volume: 30, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Disease;

2009
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb

2009
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
    Clinical cardiology, 2009, Volume: 32, Issue:3

    Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female;

2009
The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
    American heart journal, 2009, Volume: 157, Issue:5

    Topics: Aged; Clopidogrel; Coronary Stenosis; Drug Administration Schedule; Drug-Eluting Stents; Female; Fol

2009
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
    Tennessee medicine : journal of the Tennessee Medical Association, 2009, Volume: 102, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio

2009
Invited commentary.
    The Annals of thoracic surgery, 2009, Volume: 88, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Graft Survival; Hum

2009
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:19

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro

2009
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
    European heart journal, 2009, Volume: 30, Issue:22

    Topics: Aged; Blood Vessel Prosthesis; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Graft

2009
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
    The American journal of cardiology, 2009, Aug-15, Volume: 104, Issue:4

    Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug Resistan

2009
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
    European heart journal, 2010, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea

2010
Platelet aggregation in intracranial stents may mimic in-stent restenosis.
    AJNR. American journal of neuroradiology, 2010, Volume: 31, Issue:3

    Topics: Cerebral Angiography; Clopidogrel; Diagnosis, Differential; Drug Resistance; Graft Occlusion, Vascul

2010
Stent thrombosis: who's guilty?
    European heart journal, 2009, Volume: 30, Issue:22

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis; Cardiology;

2009
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
    Texas Heart Institute journal, 2009, Volume: 36, Issue:5

    Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents;

2009
Perioperative management of the patient with a coronary stent.
    Current opinion in anaesthesiology, 2010, Volume: 23, Issue:1

    Topics: Algorithms; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent

2010
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
    European heart journal, 2010, Volume: 31, Issue:6

    Topics: Blood Vessel Prosthesis; Clopidogrel; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Platel

2010
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
    European heart journal, 2010, Volume: 31, Issue:24

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Vessel Prosthesi

2010
Genetic variability in response to clopidogrel therapy: clinical implications.
    European heart journal, 2010, Volume: 31, Issue:24

    Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2

2010
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2

    Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro

2011
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    European heart journal, 2011, Volume: 32, Issue:13

    Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin

2011
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting surgery.
    American heart journal, 2011, Volume: 161, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Graft

2011
Regarding "results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial".
    Journal of vascular surgery, 2011, Volume: 53, Issue:5

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Graft Occlusi

2011
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    European heart journal, 2011, Volume: 32, Issue:23

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor

2011
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
    Circulation, 2011, Aug-09, Volume: 124, Issue:6

    Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr

2011
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
    Circulation, 2011, Aug-09, Volume: 124, Issue:6

    Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary

2011
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:2

    Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas

2012
Short thromboelastography and the identification of high platelet reactivity while on and off therapy.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:9

    Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Graft Occlusion, Vascular; Humans; Male;

2012
Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance;

2012
Utility of VasoCT in the treatment of intracranial aneurysm with flow-diverter stents.
    Journal of neurosurgery, 2012, Volume: 117, Issue:1

    Topics: Adult; Aged; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Catheterization; Cereb

2012
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:18

    Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact

2012
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
    European heart journal, 2012, Volume: 33, Issue:20

    Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf

2012
The use of the X-Sizer transluminal extraction catheter as an adjunct to stenting of occluded saphenous vein grafts.
    The Journal of invasive cardiology, 2003, Volume: 15, Issue:5

    Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Catheters, I

2003
Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation.
    Circulation, 2003, Jun-10, Volume: 107, Issue:22

    Topics: Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Graft Occlusion, Vascular; Heptanoic Ac

2003
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap

2003
Resistance to antiplatelet drugs: is it real or relevant?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004, Volume: 62, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid

2004
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004, Volume: 62, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy;

2004
[Cardiovascular pharmacology].
    Der Internist, 2004, Volume: 45, Issue:10

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl

2004
Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study.
    Journal of vascular surgery, 2005, Volume: 41, Issue:4

    Topics: Aged; Aged, 80 and over; Aneurysm; Angioplasty; Blood Vessel Prosthesis Implantation; Clopidogrel; F

2005
Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases.
    International journal of cardiovascular interventions, 2004, Volume: 6, Issue:3-4

    Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Female; Follow-

2004
Management and prevention of thrombotic stent occlusion.
    European heart journal, 2005, Volume: 26, Issue:21

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Emergency Treatment; Graft Occ

2005
Feasibility trial of carotid stenting with and without an embolus protection device.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2005, Volume: 12, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo

2005
Idiopathic spontaneous coronary artery dissection and drug-eluting stents.
    International journal of cardiology, 2006, Oct-10, Volume: 112, Issue:3

    Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Female; Gra

2006
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
    Clinical trials (London, England), 2005, Volume: 2, Issue:5

    Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas

2005
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
    Clinical trials (London, England), 2005, Volume: 2, Issue:5

    Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas

2005
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
    Clinical trials (London, England), 2005, Volume: 2, Issue:5

    Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas

2005
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
    Clinical trials (London, England), 2005, Volume: 2, Issue:5

    Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas

2005
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
    Circulation, 2006, Feb-28, Volume: 113, Issue:8

    Topics: Aged; Angiography; Case-Control Studies; Clopidogrel; Drug Delivery Systems; Female; Follow-Up Studi

2006
Images in cardiology. Unexpected response of saphenous vein graft occlusion to antiplatelet drugs.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Platelet Aggregation Inhibitors

2006
Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery.
    The heart surgery forum, 2006, Volume: 9, Issue:6

    Topics: Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Female; Graft Occlusion, Vascular; Gr

2006
What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:2

    Topics: Aged; Aged, 80 and over; Angioscopy; Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusio

2007
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:6

    Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co

2007
Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance.
    Postgraduate medical journal, 2008, Volume: 84, Issue:990

    Topics: Abciximab; Aged; Antibiotics, Antitubercular; Antibodies, Monoclonal; Clopidogrel; Drug Interactions

2008
Randomized trials in hemodialysis patients: time to step up to the plate.
    JAMA, 2008, May-14, Volume: 299, Issue:18

    Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation

2008
[Results in peripheral arterial revascularization with the use of various antiaggregating substances].
    Revista clinica espanola, 1984, May-31, Volume: 173, Issue:4

    Topics: Adult; Aged; Anticoagulants; Blood Vessel Prosthesis; Dicumarol; Graft Occlusion, Vascular; Humans;

1984
Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 1995, Volume: 9, Issue:3

    Topics: Anticoagulants; Aspirin; Data Collection; Dipyridamole; Drug Utilization; Graft Occlusion, Vascular;

1995
[Stent after-care: new approaches to coagulation inhibiting therapy].
    Herz, 1995, Volume: 20, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease;

1995
The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic model.
    Plastic and reconstructive surgery, 1995, Volume: 95, Issue:7

    Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Graft Occlusion, Vascular; Male; Microsurger

1995
[Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].
    Archives des maladies du coeur et des vaisseaux, 1994, Volume: 87, Issue:11

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coron

1994
[An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule].
    Nihon Geka Gakkai zasshi, 1994, Volume: 95, Issue:10

    Topics: Angioscopy; Animals; Antithrombins; Aorta, Abdominal; Arginine; Blood Coagulation; Blood Vessel Pros

1994
Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study.
    International angiology : a journal of the International Union of Angiology, 1996, Volume: 15, Issue:1

    Topics: Animals; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Thrombosis; Endothelium, Vascular

1996
Antiplatelet therapy and patency of saphenous-vein bypass grafts in the legs.
    The New England journal of medicine, 1998, May-07, Volume: 338, Issue:19

    Topics: Aspirin; Graft Occlusion, Vascular; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhib

1998
Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.
    European heart journal, 1998, Volume: 19, Issue:10

    Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Blood Platelets; Clopidogrel; Corona

1998
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts.
    Chest, 1998, Volume: 114, Issue:5 Suppl

    Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Graft Occlusion,

1998
Elective Wiktor GX stenting for symptomatic stenosis in old aortocoronary saphenous vein bypass grafts: the Antwerp experience.
    The Journal of invasive cardiology, 1999, Volume: 11, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Hum

1999
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
    The Canadian journal of cardiology, 2000, Volume: 16, Issue:4

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up

2000
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2000, Volume: 50, Issue:4

    Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet

2000
Risk of neutropenia with clopidogrel.
    Journal of the American College of Cardiology, 2000, Volume: 36, Issue:4

    Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Disease; Graft Occlusion, Vascular; Huma

2000
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2001, Volume: 52, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor

2001
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
    Japanese circulation journal, 2001, Volume: 65, Issue:4

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang

2001
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
    Journal of thrombosis and thrombolysis, 2001, Volume: 11, Issue:2

    Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod

2001
Bench to bedside: the development of rapamycin and its application to stent restenosis.
    Circulation, 2001, Aug-21, Volume: 104, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Animals; Calcineurin Inhibitors; Carrier Proteins; Cell Cycle Protei

2001
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2001, Volume: 22, Issue:4

    Topics: Animals; Aspirin; Blood Vessel Prosthesis; Carotid Artery, Common; Clopidogrel; Dogs; Drug Therapy,

2001
Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting.
    Platelets, 2001, Volume: 12, Issue:8

    Topics: Arteries; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Pe

2001
Blood compatibility of venous prosthesis made of textile or non-textile material.
    Thrombosis research, 1992, May-15, Volume: 66, Issue:4

    Topics: Animals; Biocompatible Materials; Blood Vessel Prosthesis; Endothelium, Vascular; Erythrocytes; Fibr

1992
[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats].
    Chirurgie; memoires de l'Academie de chirurgie, 1991, Volume: 117, Issue:9

    Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Collagen; Disease Models, Animal; Fistula; Graft Oc

1991
The pathogenesis of thrombosis in venous prostheses.
    European journal of vascular surgery, 1990, Volume: 4, Issue:6

    Topics: Animals; Blood Vessel Prosthesis; Graft Occlusion, Vascular; Male; Microscopy, Electron, Scanning; P

1990
[Role of platelet anti-aggregants in cardiovascular surgery].
    Revue medicale de Liege, 1987, May-15, Volume: 42, Issue:10

    Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Platelet Aggregati

1987
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
    International journal of tissue reactions, 1986, Volume: 8, Issue:2

    Topics: Acrylates; Animals; Arterioles; Azathioprine; Blood Platelets; Capillaries; Graft Occlusion, Vascula

1986
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
    Revue medicale de Liege, 1987, May-15, Volume: 42, Issue:10

    Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo

1987
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
    Journal of vascular surgery, 1986, Volume: 4, Issue:2

    Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Arter

1986